Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus

BACKGROUND: Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, reduces hyperglycemia and body weight by inhibiting renal glucose reabsorption. However, only a few studies have demonstrated efficacy of dapagliflozin for type 2 diabetic patients in Korea. We evaluated the efficacy and safety o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Obes Metab Syndr
Autors principals: Cho, Hyun A, Jung, Young Lee, Lee, Yong Hoon, Lee, Yu Chang, Lee, Jung Eun, Lee, Sol Jae, Jeong, Su Jin, Kim, Chong Hwa
Format: Artigo
Idioma:Inglês
Publicat: Korean Society for the Study of Obesity 2017
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6484898/
https://ncbi.nlm.nih.gov/pubmed/31089504
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7570/jomes.2017.26.2.107
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars